Infectious Disease Testing: The $47 Billion Market Opportunity Clinical Labs Cannot Afford to Miss
The global infectious disease diagnostics market reached $47 billion in 2024 and is projected to exceed $72 billion by 2030. For clinical laboratories, this represents the most significant revenue expansion opportunity in two decades—if your operational infrastructure can capture it.
COVID-19 permanently reset stakeholder expectations around diagnostic speed, capacity, and data transparency. Payers now demand 24-hour turnaround times for infectious disease panels. Public health authorities require real-time electronic reporting. Patients expect digital result delivery. Healthcare systems are consolidating lab contracts based on throughput reliability during surge conditions.
These aren’t temporary market dynamics—they’re the new competitive baseline. Labs that cannot scale efficiently, report compliantly, and demonstrate capacity resilience are losing contracts worth $2M-$8M annually to competitors with modern infrastructure.
Read More
